Work

Ethical challenges raised by osteoporosis-related clinical trials

Year: 2023

Type: article

Abstract: Introduction:Low bone mineral density (BMD), which mainly encompasses osteoporosis and osteopenia, is a chronic bone metabolic condition characterized by impaired bone microstructure and reduced bone mass.This condition elevates the risk of fractures in different parts of the body, resulting in a substantial economic, societal, and health burden.It is projected that the global prevalence of hip fractures is expected to increase by 240% for women and 310% for men by 2050 (1, 2).In recent decades, there have been significant advancements in both the availability of novel medications for treating osteoporosis and our understanding of the disease's pathogenesis.In the late 1980s, treatment options for postmenopausal women with osteoporosis were limited to estrogen replacement or, perhaps, calcitonin, in addition to calcium and vitamin D supplementation (3).

Source: Journal of Medical Ethics and History of Medicine

DOI: 10.18502/jmehm.v16i7.14302

Authors: Maryam Mirahmad, Sayed Mahmoud Sajjadi-Jazi, Fariba Asghari, Bagher Larijani

Institutions: Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences

Language: English

Topic: Ethics in Clinical Research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4389515958